SCLXW:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.1

Change

+0.00 (+0.81)%

Market Cap

N/A

Volume

670.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-19 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

+0.88 (+1.28%)

USD 209.55B
AMGN Amgen Inc

+3.44 (+1.26%)

USD 151.21B
SNY Sanofi ADR

+0.60 (+1.16%)

USD 126.38B
GILD Gilead Sciences Inc

+3.66 (+3.57%)

USD 122.21B
BIIB Biogen Inc

+3.85 (+3.07%)

USD 17.35B
GRFS Grifols SA ADR

+0.24 (+3.09%)

USD 5.91B
AMRN Amarin Corporation PLC

+0.32 (+3.02%)

USD 0.23B
MIRA MIRA Pharmaceuticals, Inc. Com..

-0.13 (-8.97%)

USD 0.02B
SCLX Scilex Holding Company

+0.49 (+11.52%)

N/A

ETFs Containing SCLXW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -52.38% 20% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -52.38% 20% F 10% F
Trailing 12 Months  
Capital Gain -67.28% 20% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -67.28% 20% F 12% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -29.06% 22% F 8% B-
Dividend Return -29.06% 22% F 8% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 43.95% 22% F 40% F
Risk Adjusted Return -66.12% 33% F 11% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector